There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The experience with MVAC (methotrexate, vinblastine, Adriamycin and cisplatin) chemotherapy
in advanced urothelial cancer is reviewed with emphasis on toxicity and efficacy.